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Background/aim: Severe neonatal hyperbilirubinemia is an important cause of morbidity and mortality in developing countries. The
aim was to assess etiologic reasons for development of severe hyperbilirubinemia and define risk factors for exchange transfusion and
acute bilirubin encephalopathy (ABE) in Şanlıurfa located in the southeast region of Turkey.
Materials and methods: An observational cohort study included 115 infants with ≥35 weeks of gestation admitted with diagnosis of
severe hyperbilirubinemia in a period of 18 months. Potential risk factors associated with exchange transfusion and development of
ABE were analyzed.
Results: Among 115 infants, 67 (58.3%) received exchange transfusion and 45 (39.1%) developed ABE. Rh isoimmunization (OR: 24.6,
95% CI = 2.2–271, P = 0.009), glucose-6-phosphate dehydrogenase deficiency (G6PD) (OR: 21.1, 95% CI = 1.8–238.4, P = 0.01), early
discharge (OR: 14.4, 95% CI = 4.2–48.9, P ≤ 0.001), and male sex (OR: 4.3, 95% CI = 1.3–14.1, P = 0.02) were independently associated
with an increased risk for exchange transfusion. Being a refugee (OR: 6.8, 95% CI = 1.8–25.8, P = 0.005) and G6PD deficiency (OR: 9.9,
95% CI = 1.3–71.9, P = 0.02) were associated with development of ABE.
Conclusion: Early discharge, Rh isoimmunization, and G6PD deficiency are significant risk factors for severe hyperbilirubinemia
and exchange transfusion. Prevention of early hospital discharges, family education to increase awareness for hazardous effects of
hyperbilirubinemia, and early follow-up visits after discharge would reduce the disease burden.
Key words: Neonatal hyperbilirubinemia, exchange transfusion, bilirubin encephalopathy, neurotoxicity, glucose-6-phosphate
dehydrogenase deficiency

1. Introduction
Neonatal jaundice is usually a physiologic condition and
is one of the most common causes of hospital admissions
in otherwise healthy newborns [1,2]. However, in some
infants the condition can be severe enough to cause
serious hyperbilirubinemia progressing to acute bilirubin
encephalopathy (ABE) and kernicterus [3–6].
With implementation of standardized and harmonized
guidelines for management of hyperbilirubinemia, the
incidence of severe hyperbilirubinemia has decreased
markedly in high income countries (HICs) [1,7–11].
However, it is still an important problem resulting in
significant disability and mortality in low and middle
income countries (LMICs) [12–15]. The incidence of
severe neonatal hyperbilirubinemia and ABE in Turkey

is reported to be higher than in HICs and lower than in
LMICs [16]. Şanlıurfa, located in the southeast region
of Turkey, has the highest birth rate in Turkey with 4.29
children per year.1 Also, it is one of the cities harboring the
highest Syrian refugee population, composing 23.6% of its
population.2
The aim of this study was to assess etiologic reasons for
the development of severe hyperbilirubinemia and define
risk factors for exchange transfusion and ABE in Şanlıurfa.
2. Material and methods
This single-center observational cohort study was
conducted at Şanlıurfa Training and Research Hospital
between June 2017 and December 2018. Sixty thousand
live births occur per year in Şanlıurfa. About 50% of all

Turkish Statistical Institute (TÜRKSAT), Ankara. Population and demography statistics 2017. Available from http://www.turkstat.gov.
tr/UstMenu.do?metod=temelist (18 December 2018, date last accessed).
2
Republic of Turkey Ministry of Interior Directorate General of Migration Management, Ankara. Migration Statistics 2018. Available
from http://www.goc.gov.tr/icerik6/temporary-protection_915_1024_4748_icerik (25 January 2019, date last accessed).
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births take place in the Şanlıurfa Training and Research
Hospital. The neonatal intensive care unit (NICU) of the
hospital is the most important third level referral center
with 107 bed capacity in the city. Another third level
referral center for severe hyperbilirubinemia cases is the
NICU of Harran University. According to the data obtained
from the NICU of Harran University, about 30% of severe
hyperbilirubinemia cases were admitted to their unit.
Infants with severe hyperbilirubinemia are mostly referred
to the NICU of Şanlıurfa Training and Research Hospital
from the city center and districts and the unit serves about
2/3 of all severe hyperbilirubinemia cases in the whole
city. Infants with ≥35 weeks of gestation, postnatal age
of ≤14 days, and diagnosis of severe hyperbilirubinemia
at admission, defined as serum bilirubin level at or above
the exchange transfusion threshold according to the
guidelines of the American Academy of Pediatrics (AAP)
for exchange transfusion, were included in the study [7].
Infants born at <35 weeks of gestation and with congenital
/chromosomal anomalies were excluded.
The study was approved by the Harran University
Institutional Ethics Committee (No: 74059997-05004.04/05.07.18). Informed parental consent was obtained
for each infant before the enrollment.
Patients were managed according to unit protocols
based on the recommendations of the AAP for management
of hyperbilirubinemia in infants with 35 or more weeks of
gestation [7]. Accordingly, infants having findings of acute
bilirubin encephalopathy or serum bilirubin levels that
were 5 mg/dL above the exchange transfusion threshold
underwent immediate exchange transfusion. For infants
whose total serum bilirubin level was at or slightly above
the exchange transfusion threshold, exchange transfusion
was performed if serum bilirubin concentrations remained
above the threshold levels after 3–4 h of intensive
phototherapy. Hemolytic jaundice was defined as presence
of anemia, hyperbilirubinemia, and hemolysis findings
in peripheral smear. Direct Coombs test positivity was
accepted as a supportive finding for hemolytic jaundice.
Intravenous immunoglobulin (IVIG) was used in infants
having hemolytic findings with direct Coombs positivity
and bilirubin levels at exchange transfusion threshold. A
neurologic evaluation was performed at admission and in
the first 6 h of admission. Bilirubin induced neurological
dysfunction score (BIND) was used to evaluate ABE [17].
According to the BIND score, ABE was graded as mild,
moderate, or severe.
Birth weight, gestational age, sex, delivery type,
maternal age, parity, early discharge, being a refugee,
postnatal age of admission, postnatal age of exchange
transfusion, weight loss on admission, total bilirubin
level (mg/dL), bilirubin/albumin ratio, defined cause
of hyperbilirubinemia, ABO incompatibility, Rh

104

isoimmunization, glucose-6-phosphate dehydrogenase
(G6PD) deficiency, and sepsis were recorded.
G6PD activity was measured quantitatively by
spectrophotometry with the cobas c501 analyzer (F.
Hoffmann-La Roche Ltd., USA).
Early discharge was defined as discharge at 12 h after
spontaneous vaginal delivery and discharge at 24 h after
cesarean section (CS).
Sepsis was defined as presence of clinical signs of sepsis
associated with (1) a positive blood culture and/or (2) an
elevated c-reactive protein level, total leukocyte count
of >25,000/mm3 or <5000/mm3, an immature to total
neutrophil ratio of >0.2, or a band count of >10%.
2.1. Statistical analysis
Categorical data were expressed as frequencies and
percentages and continuous data were expressed as means
and standard deviation (SD) and medians and minimum–
maximum. Student’s t-test was used for normally
distributed continuous variables and the Mann–Whitney
U test was used for continuous variables that were not
normally distributed. The chi-square test was used to
analyze the categorical data, along with Fischer’s exact test
when applicable. Risk factors associated with exchange
transfusion and development of ABE were analyzed
and multivariate binary logistic regression analysis with
entry method was performed for significant risk factors
with a P-value of <0.1 derived from univariate analysis.
Adjusted odds ratios (OR) and 95% confidence interval
(CI) for independent risk factors associated with exchange
transfusion and development of ABE were analyzed.
Collinear variables were not included in the same model
to avoid issues with multicollinearity. All statistics were
analyzed using SPSS 17.0 for Windows (SPSS Inc., Chicago,
IL, USA). P < 0.05 was considered significant.
3. Results
Between June 2017 and December 2018, there were about
90,000 live births in Şanlıurfa. In the study period, 3200
infants were hospitalized in the NICU of Şanlıurfa Training
and Research Hospital. Out of these, 115 (3.6%) suffered
from severe hyperbilirubinemia. The characteristics of the
studied infants are presented in Table 1. The infants’ mean
birth weight was 2935 ± 442 g and median gestational age
was 38 (35–39) weeks. In total 57 (49.6%) infants were
males and 42 (36.5%) infants were delivered by CS. The
median postnatal age at admission was 5 (1–14) days. The
mean total serum bilirubin concentration at admission
was 28.2 ± 7.9 mg/dL. Fifty infants (43.5%) had a bilirubin
concentration above 30 mg/dL at admission. The mean
bilirubin/albumin ratio was 7.9 ± 2.2 and in 78 (67.8%)
infants it was >6.8, while in 45 (39.1%) infants it was >8.6.
The mean maternal age was 27.3 ± 6.5 and 20 (17.4%)
women gave birth to their first child. Sixty-three (54.8%)
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Table 1. Characteristics of the study group.
Study infants
n = 115
Birth weight, ga

2935 ± 442

Gestational age, weeks

38 (35–39)

Male sex, n (%)

57 (49.6)

b

Cesarean delivery, n (%)

42 (36.5)

Maternal age, years

27.3 ± 6.5

a

Parity, nb

3 (1–12)

Postnatal age of admission, days

b

5 (1–14)

Postnatal age of exchange transfusion, hb

100 (24–244)

Early discharge, n (%)

63 (54.8)

Being refugee, n (%)
Total serum bilirubin, mg/dL

32 (27.8)
a

28.2 ± 7.9

Bilirubin/albumin, (ratio)a

7.9 ± 2.2

ABO incompatibility, n (%)

35 (30.4)

Lack of proper feeding and dehydration, n (%) 24 (20.9)

a

G6PD deficiency, n (%)

15 (13)

Rh isoimmunization, n (%)

13 (11.3)

Subgroup incompatibility, n (%)

3 (2.6)

Sepsis, n (%)

3 (2.6)

Galactosemia, n (%)

2 (1.7)

Unknown etiology, n (%)

20 (17.4)

Mean ± SD, b Median (min–max).

infants were discharged early and 32 (27.8%) infants were
Syrian refugees.
The
most
common
etiology
for
severe
hyperbilirubinemia was hemolytic reasons (n = 51) (44.3%)
with ABO blood incompatibility being the leading cause
(n = 35) (30.4%). Out of the 115 severe hyperbilirubinemia
cases, 24 were due to improper feeding and dehydration
(20.9%) and 15 were due to G6PD deficiency (13%) as
the second and third most common reasons, respectively
(Table 1). In 17.4% of infants (n = 20) the underlying
etiology was not defined. Sepsis and galactosemia were
other rare etiologies.
Exchange transfusion was performed for 67 patients
(58.3%). The median postnatal age for exchange
transfusion was 100 (24–244) h. The descriptive data
of infants with and without exchange transfusion are
presented in Table 2. Hemolytic causes such as ABO blood
group incompatibility, Rh isoimmunization, and subgroup
incompatibility constituted the most common etiologic
reasons for exchange transfusion (n = 28) (41.8%). The
second most common etiology was G6PD deficiency in

the exchange transfusion group. The frequencies of G6PD
deficiency (14 (20.9%) vs. 1 (2.1%), P = 0.02) and Rh
isoimmunization (12 (17.9%) vs. 1 (2.1%), P = 0.008) were
significantly higher in the exchange transfusion group
when compared to infants who were not transfused (Table
2). In multiple logistic regression analysis, male sex (OR:
4.3, 95% CI = 1.3–14.1, P = 0.02), early discharge (OR: 14.4,
95% CI = 4.2–48.9, P ≤ 0.001), G6PD deficiency (OR: 21.1,
95% CI = 1.8–238.4, P = 0.01), and Rh isoimmunization
(OR: 24.6, 95% CI = 2.2–271, P = 0.009) were found to
be independently associated with an increased risk for
exchange transfusion (Table 3).
Acute bilirubin encephalopathy developed in 45
(39.1%) infants. Eight infants had stage I, 28 infants had
stage II, and 9 infants had stage III ABE. All infants with
ABE underwent exchange transfusion except 2 infants.
Characteristics of infants with and without ABE are
summarized in Table 4. The most common etiologic reason
for severe hyperbilirubinemia was G6PD deficiency (13
(28.9%) vs. 2 (2.9%), P ≤ 0.001) in infants with ABE. The
second most common reason was Rh isoimmunization (8
(17.8%) vs. 5 (7.1%), P = 0.08) (Table 4). Multiple logistic
regression analysis revealed that being a refugee (OR: 6.8,
95% CI = 1.8–25.8, P = 0.005) and G6PD deficiency (OR:
9.9, 95% CI = 1.3–71.9, P = 0.02) were independently
associated with development of ABE in infants with severe
hyperbilirubinemia (Table 5).
The mortality rate was 7% in the whole group; 87.5% of
them were male and 50% were refugees. The mean postnatal
day of admission was 3.5 days. The etiologic reasons were
Rh isoimmunization in 3 (37.5%), G6PD deficiency in 3
(37.5%), ABO incompatibility in 1 (12.5%), and subgroup
incompatibility in 1 (12.5%) of them. Exchange transfusion
was performed for all 8 infants. All of them died within 48
h of admission. In all 8 infants c-reactive protein and total
leukocyte values were within normal ranges and blood
cultures were negative; correspondingly, the diagnosis of
sepsis was excluded. Evaluations for metabolic diseases
with tandem mass spectrometry and blood and urine
amino acid analysis also revealed no significant pathology.
All infants had severe ABE and 6 out of 8 infants were
endotracheally intubated due to irregular and apneic
breathing pattern at time of admission.
4. Discussion
In our study, more than half of the infants having severe
hyperbilirubinemia underwent exchange transfusion
and more than one-third developed ABE at admission.
The most common underlying etiology for severe
hyperbilirubinemia and exchange transfusion was found
to be hemolytic reasons, consistent with the literature. A
significant association between birth weight, male sex,
early discharge, Rh isoimmunization, G6PD deficiency,
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Table 2. Demographic and clinical characteristics of infants with and without exchange transfusion.
Exchange transfusion
n = 67

Without exchange
transfusion n = 48

P

2852 ± 456

3055 ± 397

0.02*

Gestational age, weeks

38 (35–39)

38 (35–39)

0.2

Male sex, n (%)

39 (58.2)

18 (37.5)

0.028*

Cesarean delivery, n (%)

23 (34.3)

19 (39.6)

0.56

Maternal age, years

27.6 ± 6.4

27 ± 6.5

0.6

3 (1–11)

2 (1–12)

0.07

Birth weight, ga
b

a

Parity, nb
Postnatal age of admission, days

4 (1–10)

5 (1–14)

0.85

Early discharge, n (%)

50 (74.6)

13 (27.1)

<0.001*

Being refugee, n (%)

18 (26.9)

14 (29.2)

0.78

Total serum bilirubin, mg/dLa

31.9 ± 7.3

23 ± 5.6

<0.001*

Bilirubin/albumin, (ratio)

9±2

6.4 ± 1.6

<0.001*

Bilirubin/albumin > 6.8, n (%)

59 (88.1)

19 (39.6)

<0.001*

ABO incompatibility, n (%)

14 (20.9)

21 (43.8)

0.009*

G6PD deficiency, n (%)

14 (20.9)

1 (2.1)

0.02*

Rh isoimmunization, n (%)

12 (17.9)

1 (2.1)

0.008*

Lack of proper feeding, n (%)

10 (14.9)

14 (29.2)

0.064

Mortality, n (%)

8 (11.9)

0 (0)

0.02*

b

a

G6PD: Glucose 6-phosphate dehydrogenase deficiency.
a
Mean ± SD, b Median (min–max), * P < 0.05.
Table 3. Multivariate analysis of risk factors associated with
exchange transfusion.
Variable

OR

95% CI

P

Birth weight

0.99

0.99–1

0.02

Rh isoimmunization

24.6

2.2–271

0.009

Male sex

4.3

1.3–14.1

0.02

G6PD deficiency

21.1

1.8–238.4

0.01

ABO incompatibility

1.3

0.4–4.3

0.7

Early discharge

14.4

4.2–48.9

<0.001

Lack of proper feeding

1.7

0.5–13.4

0.3

G6PD: Glucose 6-phosphate dehydrogenase deficiency.

and increased risk of exchange transfusion was observed.
While G6PD deficiency was the third most common
etiologic reason in the whole population, it was the
second most common underlying etiology for exchange
transfusion cases. Strikingly, G6PD deficiency was the
leading cause for development of ABE.
In the study period 90 thousand live births took place
in Şanlıurfa. On the basis of the knowledge that 2/3 of all
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cases of severe hyperbilirubinemia were hospitalized in
the NICU of Şanlıurfa Training and Research Hospital, the
prevalence of severe hyperbilirubinemia was estimated to
be 191/100,000 live births. The prevalence of ABE could be
estimated as 71/100,000 live births. The incidence of severe
hyperbilirubinemia is reported to be 7.1–45/100,000 live
births in westernized HICs [10,11,18,19]. The situation is
much worse in LMICs with reported frequencies of ABE
of up to 1749/100,000 live births [13,20].
Similar to the results of the Turkish Neonatal Jaundice
Registry, the most common risk factors for development
of severe neonatal jaundice were hemolytic reasons,
improper feeding, and dehydration. The most common
hemolytic etiology was ABO blood group incompatibility
in accordance with the literature [11,13,16]. However,
Rh isoimmunization and G6PD deficiency caused more
severe hyperbilirubinemia, as seen in our results. In
previous research, hemolytic disease or direct Coombs
test positivity was associated with higher risk of ABE and
permanent neurological abnormalities [20–23]. The Child
Health Epidemiology Reference Group’s modeling study
estimated that 78% of cases of extreme hyperbilirubinemia
are attributable to Rh isoimmunization, 6% to G6PD
deficiency, and 17% to other etiologies, and 80% of
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Table 4. Demographic and clinical characteristics of infants with and without ABE.
With ABE
n = 45

Without ABE
n = 70

P

2899 ± 509

2958 ± 399

0.51

Gestational age, weeks

38 (35–39)

38 (35–39)

0.45

Male sex, n (%)

25 (55.6)

32 (45.7)

0.3

Cesarean delivery, n (%)

15 (33.3)

27 (38.6)

0.56

Maternal age, years

26.9 ± 6.4

27.7 ± 6.5

0.55

3 (1–12)

3 (1–11)

0.23

Birth weight, ga
b

a

Parity, nb
Postnatal age of admission, days

4 (1–11)

5 (1–14)

0.48

Early discharge, n (%)

34 (75.6)

29 (41.4)

<0.001*

Being refugee, n (%)

17 (37.8)

15 (21.4)

0.056

Total serum bilirubin, mg/dLa

33.9 ± 6.6

24.6 ± 6.5

<0.001*

Bilirubin/albumin, (ratio)

9.6 ± 1.9

6.9 ± 1.8

<0.001*

Bilirubin/albumin >8.6

34 (75.6)

11 (15.7)

<0.001*

G6PD deficiency, n (%)

13 (28.9)

2 (2.9)

<0.001*

Rh isoimmunization, n (%)

8 (17.8)

5 (7.1)

0.08

ABO incompatibility, n (%)

6 (13.3)

29 (41.4)

0.001*

Mortality, n (%)

8 (17.8)

0 (0)

<0.001*

b

a

ABE: Acute bilirubin encephalopathy, G6PD: Glucose 6-phosphate dehydrogenase
deficiency.
a
Mean ± SD, b Median (min–max), * P < 0.05.
Table 5. Multivariate analysis of risk factors associated with
development of ABE.
Variable

OR

95% CI

P

G6PD deficiency

9.9

1.3–71.9

0.02

Early discharge

2.5

0.8–7.4

0.17

Being refugee

6.8

1.8–25.8

0.005

Rh isoimmunization

1.7

0.6–4.9

0.09

ABE: Acute bilirubin encephalopathy,
6-phosphate dehydrogenase deficiency.

G6PD:

Glucose

affected infants are in countries with a mortality rate
of >15/1000 live births. The model expected no severe
hyperbilirubinemia due to Rh disease in HIC [24]. The
Turkish Neonatal Registry reported the frequency of Rh
disease as 5.4 % of all admissions due to hyperbilirubinemia
[16]. Rh isoimmunization constituted 11.3% of all severe
hyperbilirubinemia cases in our study population but its
frequency increased to about 18% among infants receiving
exchange transfusion and developing ABE.
G6PD deficiency leads to hyperbilirubinemia by acute
hemolysis and mainly by decreased bilirubin conjugation.

Most of the time G6PD deficiency causes rapidly rising
severe hyperbilirubinemia [25,26]. Kilicdag et al. [27]
reported a significant correlation between the severity
of hyperbilirubinemia and G6PD activity. Since it is an
X-linked disease, males are more frequently affected. G6PD
deficiency was observed as 0.5% in the Turkish Neonatal
Registry data [16], but in severe hyperbilirubinemia and
ABE cases its frequency increases. The disease is mostly
prevalent in Mediterranean and Middle East regions of
the world. Şanlıurfa, by both its location and for harboring
Syrian refugees from the Middle East, is expected to have a
high prevalence of G6PD deficiency.
The rate of CS delivery was not high in our population
(36.5%), contrary to the report of Turkish Neonatal
Jaundice Registry [16]. However, the rate of early
discharge was strikingly high. This can be attributed to
low education level, long established attitudes, the desire
of the population for early discharge, and the inevitable
tendency of health professionals to allow early discharge
because of overcrowding in the hospitals in this region
of Turkey. Farhat et al. [28] reported that early discharge
before 48 h increased the risk of readmission due to
hyperbilirubinemia. Similarly, Bayoumi et al. [29]
reported higher neonatal readmissions mainly due to
hyperbilirubinemia in newborns discharged 24 h after CS
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delivery. In westernized countries, early hospital discharge
was also associated with increased rate of readmissions
due to severe hyperbilirubinemia [30,31]. In our study
population, a significant percentage of newborns were
discharged even without one night stay in hospital. The
median day of admission was about 5 days, in parallel with
previous publications [11,14]. Mean day of admission for
the infants who died due to severe hyperbilirubinemia
was 3.5 days. According to the report of Turkish Neonatal
Registry, median age at admission was 3 days and their
mean peak bilirubin concentration was around 17 mg/dL,
which was lower than in our population [16]. Thus, with
follow-up visits on the third day or just before the third
day, we would be able to diagnose hyperbilirubinemia early
and treat hyperbilirubinemia cases before they increase to
severe levels. Once the bilirubin level is elevated above
30 mg/dL or bilirubin/albumin ratio is >8.6, advanced
ABE that benefits little from therapy is often present
and mortality is increased. The American Academy of
Pediatrics and Canadian Pediatric Society recommends
follow-up for newborns 48–72 h after hospital discharge
[7,32]. Prevention of early discharges and, if it is inevitable,
predischarge bilirubin measurement as suggested by
Bhutani et al. [33], and follow-up 48 h after discharge or
on the postnatal third day of life would be strategies to
decrease severe hyperbilirubinemia cases.
The number of Syrian refugee births is increasing
every year in Turkey [34,35]. Şanlıurfa, located on the
southeastern border of Turkey, hosts a large refugee
population composing about one-fourth of its population.
Health care for these refugees is a major problem in
this region of country. In our study, being a refugee was
observed as an independent risk factor for development
of ABE. Underlying reasons for severe hyperbilirubinemia
were similar among Syrian refugees and Turkish citizens.
Refugees utilize health care facilities offered by the Turkish
government free of charge. However, most of them do
not speak Turkish and have communication problems.
Early hospital discharges combined with communication
problems lead to inadequate feeding education and

information about neonatal jaundice and the importance
of early neonatal follow-up. Most of the refugee mothers
also do not prefer to breastfeed because of sociocultural
features. Another finding is that, although statistically not
significant, the mean maternal age of Syrian refugees was
younger than that of Turkish women. We think that all
these conditions contribute to the development of severe
hyperbilirubinemia and ABE in refugee infants.
One of the limitations of the study was that not all
patients with severe hyperbilirubinemia were admitted
to hospitals and health care facilities. Some superstitions
and orientation towards nonmedical treatment options
prevent families from seeking medical care. Therefore, the
true incidence of severe hyperbilirubinemia and deaths
due to this were probably underestimated in Şanlıurfa.
Another limitation was that the incidence of
kernicterus and permanent neurologic sequelae due to
bilirubin induced neurotoxicity were not known.
In conclusion, severe hyperbilirubinemia and ABE are
still important but largely preventable conditions causing
significant disability and mortality. Early discharge, Rh
isoimmunization, and G6PD deficiency are significantly
associated with exchange transfusion and development
of ABE. During routine postnatal care, predischarge
bilirubin measurements, blood group and Rh typing, and
G6PD screening programs would be helpful to identify atrisk infants. Strategies to prevent early hospital discharges,
defining at-risk infants before discharge, maternal
education for breastfeeding, family education to gain insight
into the hazardous effects of severe hyperbilirubinemia,
early follow-up visits after discharge, and prompt and
effective treatment of recognized cases with phototherapy
would reduce undesirable and permanent morbidity and
mortality due to hyperbilirubinemia. In addition, being a
refugee is a special risk factor for development of ABE and
special considerations should be made for these infants.
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